OSE Immunotherapeutics Reports Promising Results for Cancer Vaccine in Phase 2 Pancreatic Cancer Trial

OSE Immunotherapeutics, a French biotech company, has unveiled encouraging data from its phase 2 clinical trial evaluating Tedopi, a therapeutic cancer vaccine, in combination with chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The results, presented at the American Society of Clinical Oncology (ASCO) meeting, demonstrate a significant improvement in overall survival rates compared to chemotherapy alone.

Impressive Survival Data

The study, which included 107 patients with advanced or metastatic PDAC who had not progressed after eight cycles of FOLFIRINOX induction chemotherapy, revealed a 12-month overall survival rate of 65% for patients receiving Tedopi alongside chemotherapy. This marks a substantial improvement over historical survival rates for this notoriously difficult-to-treat cancer type.

Dr. Cindy Neuzillet, the study's principal investigator, called the results "an encouraging first step towards better understanding the contribution of Tedopi in combination therapy in advanced pancreatic cancer." However, she emphasized the need for "more mature data on overall survival over a longer period."

Innovative "Pipeline in a Product" Approach

Tedopi combines 10 neo-epitopes derived from five tumor antigens, selected for their presence across various tumor types. This multi-target approach positions the vaccine as a potential "pipeline in a product" for HLA-A2 positive patients, addressing unmet needs in oncology.

Dr. Silvia Comis, Chief Clinical and Medical Research Officer at OSE, explained, "The positive results for Tedopi in pancreatic cancer are promising for this devastating disease with a poor prognosis." The company is currently running five clinical trials of Tedopi in various oncology indications, including a phase 3 study in non-small cell lung cancer (NSCLC).

Safety Profile and Future Outlook

The trial reported a manageable safety profile, with 26% of patients in the Tedopi arm experiencing serious adverse events, of which 6% were deemed related to the vaccine. Importantly, no new safety signals were observed during the study.

OSE Immunotherapeutics is set to continue its evaluation of Tedopi, with phase 2 readouts in NSCLC and ovarian cancer expected next year. These upcoming results, along with the ongoing phase 3 NSCLC trial, will be crucial in determining the full potential of this innovative cancer vaccine across multiple indications.